Treatment patterns and characteristics of headache in patients in Japan: A retrospective cross-sectional and longitudinal analysis of health insurance claims data

Cephalalgia. 2024 Jan;44(1):3331024231226177. doi: 10.1177/03331024231226177.

Abstract

Background: The present study aimed to investigate prescription patterns for patients aged over 17 years with headaches in the REZULT database.

Methods: We conducted a cross-sectional study (Study 1) of the proportion of over-prescription of acute medications (≥30 tablets/90 days for triptans, combination non-steroidal anti-inflammatory drugs (NSAIDs) and multiple types; ≥45 tablets/90 days for single NSAIDs) among patients with headache diagnosed in 2020. We longitudinally studied (Study 2) patients for >2 years from initial headache diagnosis (July 2010 to April 2022). The number of prescribed tablets was counted every 90 days.

Results: In Study 1, headache was diagnosed in 200,055 of 3,638,125 (5.5%) patients: 13,651/200,055 (6.8%) received acute medication. Single NSAIDs were prescribed to 12,297/13,651 (90.1%) patients and triptans to 1710/13,651 (12.5%). Over-prescription was found in 2262/13,651 (16.6%) patients and 1200/13,651 (8.8%) patients received prophylactic medication. In Study 2, 408,183/6,840,618 (6.0%) patients were first diagnosed with headaches, which persisted for ≥2 years. Over time, the proportion of patients over-prescribed acute medications increased. Over 2 years, 37,617/408,183 (9.2%) patients were over-prescribed acute medications and 29,313/408,183 (7.2%) patients were prescribed prophylaxis at least once.

Conclusions: According to real-world data, prophylaxis remains poorly prescribed, and both acute and prophylactic treatment rates for headaches have increased over time.

Keywords: Acute mediations; NSAIDs; artificial intelligence; medication-overuse headache; prophylaxis; triptans.

MeSH terms

  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal* / therapeutic use
  • Cross-Sectional Studies
  • Headache* / drug therapy
  • Headache* / epidemiology
  • Humans
  • Insurance, Health
  • Japan / epidemiology
  • Retrospective Studies
  • Tryptamines / therapeutic use

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Tryptamines